CO4940418A1
(es)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
USRE43932E1
(en)
|
1997-07-18 |
2013-01-15 |
Novartis Ag |
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
|
ITMI992711A1
(it)
*
|
1999-12-27 |
2001-06-27 |
Novartis Ag |
Composti organici
|
US7087608B2
(en)
*
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
CA2424470C
(en)
*
|
2000-10-27 |
2009-06-09 |
Novartis Ag |
Treatment of gastrointestinal stromal tumors
|
SI2762140T1
(sl)
|
2001-02-19 |
2017-07-31 |
Novartis Ag |
Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina
|
CN1511036B
(zh)
*
|
2001-02-27 |
2010-05-05 |
诺瓦提斯公司 |
包含信号转导抑制剂和埃坡霉素衍生物的联合形式
|
GB0108606D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Novartis Ag |
Organic compounds
|
AU2005246965B2
(en)
*
|
2001-05-16 |
2008-04-17 |
Novartis Ag |
Combination comprising N-{5-[4(4-methyl-piperazino-methyl)-bezoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
DE60219617T2
(de)
*
|
2001-05-16 |
2008-01-03 |
Novartis Ag |
Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
|
EP1704863A3
(en)
*
|
2001-05-16 |
2010-11-24 |
Novartis AG |
Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
|
AU2002345670A1
(en)
|
2001-06-14 |
2003-01-02 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
EP1408978A4
(en)
*
|
2001-06-21 |
2005-07-13 |
Ariad Pharma Inc |
NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
|
ES2274075T3
(es)
|
2001-06-29 |
2007-05-16 |
Ab Science |
Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
|
DE60223063T2
(de)
|
2001-06-29 |
2008-07-17 |
Ab Science |
C-kit inhibitoren
|
ES2266553T3
(es)
|
2001-06-29 |
2007-03-01 |
Ab Science |
Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
|
EP1401413B1
(en)
|
2001-06-29 |
2006-11-22 |
AB Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
CA2450777C
(en)
|
2001-08-10 |
2013-04-09 |
Novartis Ag |
Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
|
GB0120690D0
(en)
|
2001-08-24 |
2001-10-17 |
Novartis Ag |
Organic compounds
|
WO2003039550A1
(en)
*
|
2001-09-20 |
2003-05-15 |
Ab Science |
Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
|
EP2343366A1
(en)
|
2001-10-05 |
2011-07-13 |
Novartis AG |
Mutated Abl kinase domains
|
US7045523B2
(en)
|
2001-10-18 |
2006-05-16 |
Novartis Ag |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
|
IL161583A0
(en)
*
|
2001-10-25 |
2004-09-27 |
Wisconsin Alumni Res Found |
Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
|
GB0127922D0
(en)
*
|
2001-11-21 |
2002-01-16 |
Novartis Ag |
Organic compounds
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
AU2007201056B2
(en)
*
|
2002-01-28 |
2010-06-10 |
Hyks-Instituutti Oy |
Treatment of rheumatoid arthritis using imatinib
|
GB0201882D0
(en)
*
|
2002-01-28 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
GB0202873D0
(en)
*
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
AU2003209521A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Oregon Health And Science University (Ohsu) |
Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
|
CA2477558A1
(en)
*
|
2002-02-28 |
2003-09-04 |
Novartis Ag |
N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
DK1487424T3
(da)
*
|
2002-03-15 |
2007-01-08 |
Novartis Ag |
4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)-pyrimidin-2-yl-amino)phenyl-benzamid til behandling af Ang II-medierede sygdomme
|
AU2003226209B2
(en)
*
|
2002-03-21 |
2008-10-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibition of cell death responses induced by oxidative stress
|
AU2003216573A1
(en)
*
|
2002-04-16 |
2003-10-27 |
Issam Moussa |
Drug eluting vascular stent and method of treating hyperproliferative vascular disease
|
AU2007201830C1
(en)
*
|
2002-04-23 |
2017-09-07 |
Novartis Pharma Ag |
High drug load tablet
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
MXPA04011384A
(es)
|
2002-05-16 |
2005-02-14 |
Novartis Ag |
Uso de agentes de union del receptor edg en cancer.
|
US20060052387A1
(en)
*
|
2002-06-26 |
2006-03-09 |
Marsh Clay B |
Organic compounds
|
RU2315043C2
(ru)
*
|
2002-06-28 |
2008-01-20 |
Ниппон Синяку Ко., Лтд. |
Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
|
AU2003244922A1
(en)
*
|
2002-06-28 |
2004-01-19 |
The Administrators Of The Tulane Educational Fund |
4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
|
AU2003252047A1
(en)
*
|
2002-07-18 |
2004-02-09 |
Medtronic Ave Inc. |
Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
|
WO2004009089A1
(en)
*
|
2002-07-19 |
2004-01-29 |
Ludwig Institute For Cancer Research |
Enhancing the effect of radioimmunotherapy in the treatment of tumors
|
BR0312873A
(pt)
*
|
2002-07-24 |
2005-06-28 |
Univ Cincinnati |
4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
|
AU2003232376A1
(en)
*
|
2002-07-24 |
2004-02-09 |
Novartis Ag |
4-(4-methylpiperazin-1-ylmethyl)-n-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating anaplastic thyroid cancer
|
AU2003250701A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
US8450302B2
(en)
|
2002-08-02 |
2013-05-28 |
Ab Science |
2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
EP1525200B1
(en)
|
2002-08-02 |
2007-10-10 |
AB Science |
2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
CA2439440A1
(en)
|
2002-09-05 |
2004-03-05 |
Emory University |
Treatment of tuberous sclerosis associated neoplasms
|
AU2003273675A1
(en)
*
|
2002-10-09 |
2004-05-04 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
WO2004037261A1
(en)
*
|
2002-10-25 |
2004-05-06 |
The Administrators Of The Tulane Educational Fund |
Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
GB2398565A
(en)
*
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
CN1764482B
(zh)
*
|
2003-04-04 |
2011-01-19 |
诺比尔生物研究所有限公司 |
血管支架
|
WO2004099186A1
(en)
|
2003-05-06 |
2004-11-18 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
AR044402A1
(es)
|
2003-05-19 |
2005-09-14 |
Irm Llc |
Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
GB0312086D0
(en)
*
|
2003-05-27 |
2003-07-02 |
Novartis Ag |
Organic compounds
|
MXPA05012739A
(es)
*
|
2003-05-27 |
2006-05-17 |
Robert Per Hagerkvist |
Uso de inhibidor de quinasa de tirosina para tratar diabetes.
|
AU2003237596A1
(en)
*
|
2003-06-02 |
2005-01-21 |
Hetero Drugs Limited |
Novel polymorphs of imatinib mesylate
|
JP2006526652A
(ja)
*
|
2003-06-03 |
2006-11-24 |
ベス・イスラエル・ディーコニス・メディカル・センター |
血管狭窄を治療するための方法及び化合物
|
CA2538523A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Novartis Ag |
Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
|
CN1950347B
(zh)
|
2003-10-23 |
2012-04-04 |
Ab科学公司 |
作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物
|
ES2324917T3
(es)
|
2003-11-18 |
2009-08-19 |
Novartis Ag |
Inhibidores de la forma mutante de kit.
|
JPWO2005063720A1
(ja)
*
|
2003-12-25 |
2007-07-19 |
日本新薬株式会社 |
アミド誘導体及び医薬
|
AR047530A1
(es)
|
2004-02-04 |
2006-01-25 |
Novartis Ag |
Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
|
PL1720853T3
(pl)
*
|
2004-02-11 |
2016-06-30 |
Natco Pharma Ltd |
Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
|
CN1309719C
(zh)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
苯氨基嘧啶衍生物及其用途
|
UA84462C2
(ru)
*
|
2004-04-02 |
2008-10-27 |
Институт Фармацевтични |
Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
|
DK2253614T3
(da)
|
2004-04-07 |
2013-01-07 |
Novartis Ag |
IAP-inhibitorer
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
CN1976708A
(zh)
*
|
2004-07-01 |
2007-06-06 |
荷兰癌症研究所 |
包含bcrp抑制剂和4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺的组合
|
WO2006024863A1
(en)
*
|
2004-09-02 |
2006-03-09 |
Cipla Limited |
Stable crystal form of imatinib mesylate and process for the preparation thereof
|
CA2591321C
(en)
|
2004-09-09 |
2013-09-24 |
Natco Pharma Limited |
Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
WO2006048890A1
(en)
*
|
2004-11-04 |
2006-05-11 |
Sun Pharmaceutical Industries Limited |
Imatinib mesylate crystal form and process for preparation thereof
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
AU2005321946B2
(en)
|
2004-12-23 |
2012-08-16 |
Deciphera Pharmaceuticals, Llc |
Enzyme modulators and treatments
|
KR20080019578A
(ko)
|
2005-04-04 |
2008-03-04 |
에이비 사이언스 |
치환된 옥사졸 유도체 및 이의 티로신 키나제 억제제로서의용도
|
US20080176879A1
(en)
|
2005-05-02 |
2008-07-24 |
Leila Alland |
Pyrimidylaminobenzamide Derivatives For Sytemic Mastocytosis
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
PL1893213T3
(pl)
|
2005-06-03 |
2010-08-31 |
Novartis Ag |
Kombinacja związków pirymidyloaminobenzamidowych i imatinibu do leczenia lub profilaktyki chorób proliferacyjnych
|
GT200600316A
(es)
*
|
2005-07-20 |
2007-04-02 |
|
Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
|
KR100674813B1
(ko)
|
2005-08-05 |
2007-01-29 |
일양약품주식회사 |
N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
|
ES2334933T3
(es)
*
|
2005-08-15 |
2010-03-17 |
Siegfried Generics International Ag |
Comprimido recubierto o granulado que contiene una piridilpirimidina.
|
CA2620835A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Novartis Ag |
Delta and epsilon crystal forms of imatinib mesylate
|
NO20220050A1
(no)
|
2005-11-21 |
2008-08-12 |
Novartis Ag |
Neuroendokrin tumorbehandling
|
KR20130140909A
(ko)
*
|
2005-11-25 |
2013-12-24 |
노파르티스 아게 |
이마티니브 메실레이트의 f, g, h, i 및 k 결정형
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
CN102861338A
(zh)
|
2006-04-05 |
2013-01-09 |
诺瓦提斯公司 |
用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
|
JP2009532503A
(ja)
|
2006-04-05 |
2009-09-10 |
ノバルティス アクチエンゲゼルシャフト |
癌を処置するための治療剤の組合せ
|
US8067421B2
(en)
*
|
2006-04-27 |
2011-11-29 |
Sicor Inc. |
Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
|
US7977348B2
(en)
*
|
2006-04-27 |
2011-07-12 |
Sicor Inc. |
Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
|
EP2311821A1
(en)
|
2006-04-27 |
2011-04-20 |
Sicor, Inc. |
Polymorphic form of Imatinib mesylate and processes for its preparation
|
US20060223816A1
(en)
*
|
2006-05-08 |
2006-10-05 |
Chemagis Ltd. |
Imatinib mesylate alpha form and production process therefor
|
AU2007247112B2
(en)
|
2006-05-09 |
2010-08-26 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
WO2008004944A1
(en)
*
|
2006-07-04 |
2008-01-10 |
Astrazeneca Ab |
Novel crystalline form ii
|
WO2008004945A1
(en)
*
|
2006-07-04 |
2008-01-10 |
Astrazeneca Ab |
Novel crystalline forms i and ii
|
US8246966B2
(en)
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
US20090324718A1
(en)
*
|
2006-09-01 |
2009-12-31 |
Ilan Zalit |
Imatinib compositions
|
MX2009003082A
(es)
|
2006-09-22 |
2009-04-01 |
Novartis Ag |
Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl.
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
US20080103305A1
(en)
*
|
2006-10-26 |
2008-05-01 |
Macdonald Peter |
Process for the preparation of imatinib
|
EP2009008A1
(en)
|
2006-10-26 |
2008-12-31 |
Sicor, Inc. |
Imatinib base, and imatinib mesylate and processes for preparation thereof
|
WO2008070350A2
(en)
|
2006-10-27 |
2008-06-12 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
EP1920767A1
(en)
*
|
2006-11-09 |
2008-05-14 |
Abbott GmbH & Co. KG |
Melt-processed imatinib dosage form
|
CA2667720A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Abbott Gmbh & Co. Kg. |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
WO2008066755A2
(en)
|
2006-11-22 |
2008-06-05 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
|
EP2121681B1
(en)
|
2007-01-11 |
2015-04-15 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
WO2008093246A2
(en)
|
2007-02-02 |
2008-08-07 |
Vegenics Limited |
Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
CN101657446B
(zh)
*
|
2007-02-13 |
2013-05-15 |
Ab科学有限公司 |
合成作为激酶抑制剂的2-氨基噻唑化合物的方法
|
WO2008100985A2
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of lbh589 with other therapeutic agents for treating cancer
|
CN101265275B
(zh)
*
|
2007-02-16 |
2012-09-05 |
中国医学科学院药物研究所 |
4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯
|
CA2680249A1
(en)
*
|
2007-03-12 |
2008-09-18 |
Dr. Reddy's Laboratories, Inc. |
Imatinib mesylate
|
US20080234286A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Chemagis Ltd. |
Stable amorphous imatinib mesylate and production process therefor
|
US7550591B2
(en)
*
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
US20090012296A1
(en)
*
|
2007-05-29 |
2009-01-08 |
Alexandr Jegorov |
Processes for the preparation of crystalline form beta of imatinib mesylate
|
PL2305263T3
(pl)
|
2007-06-07 |
2012-12-31 |
Novartis Ag |
Stabilizowane amorficzne formy mesylanu imatinibu
|
KR101041203B1
(ko)
*
|
2007-09-25 |
2011-06-13 |
테바 파마슈티컬 인더스트리즈 리미티드 |
안정한 이매티닙 조성물
|
US20090082361A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched imatinib
|
US8501740B2
(en)
*
|
2007-10-09 |
2013-08-06 |
Board Of Regents, The University Of Texas System |
Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
PT2268612E
(pt)
|
2008-03-24 |
2014-11-13 |
Novartis Ag |
Inibidores de metaloprotease de matriz à base de arilsulfonamidas
|
PL2260020T3
(pl)
|
2008-03-26 |
2015-01-30 |
Novartis Ag |
Hydroksamianowe inhibitory deacetylaz B
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
LT2300013T
(lt)
|
2008-05-21 |
2017-12-27 |
Ariad Pharmaceuticals, Inc. |
Fosforo dariniai kaip kinazių inhibitoriai
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
JP2011526292A
(ja)
|
2008-06-27 |
2011-10-06 |
インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション |
神経線維腫および関連する腫瘍を抑制および/または治療する物質および方法
|
DE102008031037A1
(de)
|
2008-06-30 |
2009-12-31 |
Dömling, Alexander, Priv.-Doz. Dr. |
Gleevec zur Anwedung in der Organtransplantation
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
US20100221221A1
(en)
*
|
2008-08-12 |
2010-09-02 |
Concert Pharmaceuticals Inc. |
N-phenyl-2-pyrimidineamine derivatives
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
EP2344161B1
(en)
|
2008-10-16 |
2018-12-19 |
Celator Pharmaceuticals, Inc. |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
EP2186514B1
(en)
*
|
2008-11-14 |
2016-06-29 |
Kinki University |
Treatment of Malignant Peripheral Nerve Sheath Tumors
|
EP2370078A1
(en)
|
2008-12-01 |
2011-10-05 |
Novartis AG |
Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
|
KR20110096584A
(ko)
|
2008-12-18 |
2011-08-30 |
노파르티스 아게 |
1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염
|
CN103204794A
(zh)
|
2008-12-18 |
2013-07-17 |
诺瓦提斯公司 |
新的盐
|
BRPI0922457A2
(pt)
|
2008-12-18 |
2015-12-15 |
Novartis Ag |
forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
SI2391366T1
(sl)
|
2009-01-29 |
2013-01-31 |
Novartis Ag |
Substituirani benzimidazoli za zdravljenje astrocitomov
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
CA2760031C
(en)
|
2009-04-28 |
2015-03-10 |
Daiichi Sankyo Company, Limited |
Acetone solvate crystals of trityl olmesartan medoxomil
|
US20100330130A1
(en)
*
|
2009-05-22 |
2010-12-30 |
Actavis Group Ptc Ehf |
Substantially pure imatinib or a pharmaceutically acceptable salt thereof
|
TW201102068A
(en)
*
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
UA105794C2
(uk)
|
2009-06-26 |
2014-06-25 |
Новартіс Аг |
1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
WO2011018454A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
CA2771532C
(en)
|
2009-08-17 |
2021-03-23 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
IN2012DN01453A
(zh)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
BR112012008075A2
(pt)
|
2009-08-26 |
2016-03-01 |
Novartis Ag |
compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
|
CZ2009570A3
(cs)
|
2009-08-26 |
2011-03-09 |
Zentiva, K. S. |
Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
|
CA2773661A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
WO2011039782A1
(en)
*
|
2009-09-29 |
2011-04-07 |
Ind-Swift Laboratories Limited |
Processes for preparing imatinib and pharmaceutically acceptable salts thereof
|
PL389357A1
(pl)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
|
MX2012005293A
(es)
|
2009-11-04 |
2012-06-19 |
Novartis Ag |
Derivados de sulfonamida heterociclicos utiles como inhibidores de mek.
|
JP6220126B2
(ja)
|
2009-11-23 |
2017-10-25 |
セルリアン・ファーマ・インコーポレイテッド |
治療的送達のためのシクロデキストリンに基づく重合体
|
CN102712648A
(zh)
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
双环杂芳基的与苯稠合的6元含氧杂环衍生物
|
CN102648188A
(zh)
|
2009-12-08 |
2012-08-22 |
诺瓦提斯公司 |
杂环磺酰胺衍生物
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011095835A1
(en)
|
2010-02-02 |
2011-08-11 |
Actavis Group Ptc Ehf |
Highly pure imatinib or a pharmaceutically acceptable salt thereof
|
BR112012020491A2
(pt)
|
2010-02-15 |
2017-10-10 |
Reliance Life Sciences Pvt Ltd |
processo para a preparação de forma alfa de mesilato de imatinib.
|
PL390611A1
(pl)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
|
CA2792472A1
(en)
*
|
2010-03-15 |
2011-09-22 |
Natco Pharma Limited |
Process for the preparation of highly pure crystalline imatinib base
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
EP2552915B1
(en)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Compounds for the treatment of hiv
|
WO2011130918A1
(zh)
|
2010-04-23 |
2011-10-27 |
上海百灵医药科技有限公司 |
一种伊马替尼的合成方法
|
EP2382976A1
(en)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
|
EA022094B1
(ru)
|
2010-06-16 |
2015-10-30 |
Такеда Фармасьютикал Компани Лимитед |
Кристаллическая форма амидного соединения
|
WO2011158255A1
(en)
*
|
2010-06-16 |
2011-12-22 |
Aptuit Laurus Private Limited |
Process for preparation of stable imatintb mesylate alpha form
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
|
EP2582680A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
EA024088B1
(ru)
|
2010-06-18 |
2016-08-31 |
КРКА, д.д., НОВО МЕСТО |
α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
RU2013110058A
(ru)
|
2010-08-11 |
2014-09-20 |
Синтон Б.В. |
Фармацевтический гранулят, содержащий иматиниба мезилат
|
TR201007005A2
(tr)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
İmatinib baz üretim yöntemi
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
RU2456280C2
(ru)
*
|
2010-08-27 |
2012-07-20 |
Общество с ограниченной ответственностью "Химфармресурс" |
Кристаллическая n-модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил] бензамида метансульфоната, способ ее получения и фармацевтическая композиция на ее основе
|
EP2627648A1
(en)
|
2010-09-16 |
2013-08-21 |
Novartis AG |
17aHYDROXYLASE/C17,20-LYASE INHIBITORS
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
CN102477031B
(zh)
*
|
2010-11-30 |
2015-07-15 |
浙江九洲药业股份有限公司 |
一种甲磺酸伊马替尼α晶型的制备方法
|
TR201010618A2
(tr)
*
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
|
BR112013015449A2
(pt)
|
2010-12-21 |
2016-09-20 |
Novartis Ag |
compostos de bi-heteroarila como inibidores de vps23
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
CN102649785B
(zh)
*
|
2011-02-23 |
2015-08-19 |
江苏先声药物研究有限公司 |
一种伊玛替尼甲烷磺酸盐β晶型的制备方法
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
CN102146073A
(zh)
*
|
2011-02-23 |
2011-08-10 |
江苏先声药物研究有限公司 |
一种伊玛替尼甲烷磺酸盐α晶型新的制备方法
|
WO2012122058A2
(en)
|
2011-03-04 |
2012-09-13 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
EP2683722A1
(en)
|
2011-03-08 |
2014-01-15 |
Novartis AG |
Fluorophenyl bicyclic heteroaryl compounds
|
PL394169A1
(pl)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
|
WO2012131711A1
(en)
|
2011-03-31 |
2012-10-04 |
Ind-Swift Laboratories Limited |
Improved process for preparation of imatinib and its mesylate salt
|
MX359399B
(es)
|
2011-04-28 |
2018-09-27 |
Novartis Ag |
Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
|
CN103501612B
(zh)
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
KR20140034898A
(ko)
|
2011-06-09 |
2014-03-20 |
노파르티스 아게 |
헤테로시클릭 술폰아미드 유도체
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
CA2840315A1
(en)
|
2011-06-27 |
2013-01-03 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
ITMI20111309A1
(it)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
Procedimento di preparazione di imatinib mesilato
|
CN102321070B
(zh)
*
|
2011-07-27 |
2013-05-22 |
江苏先声药物研究有限公司 |
反溶剂重结晶法制备伊玛替尼甲烷磺酸盐α晶型
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
WO2013063003A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
JP2014532647A
(ja)
|
2011-10-28 |
2014-12-08 |
ノバルティス アーゲー |
消化管間質腫瘍を治療する方法
|
WO2013067157A1
(en)
|
2011-11-01 |
2013-05-10 |
Modgene, Llc |
Compositions and methods for reduction of amyloid-beta load
|
WO2013080141A1
(en)
|
2011-11-29 |
2013-06-06 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
EP2604596A1
(en)
|
2011-12-16 |
2013-06-19 |
Deva Holding Anonim Sirketi |
Polymorphs of imatinib
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
JP5903499B2
(ja)
|
2011-12-22 |
2016-04-13 |
ノバルティス アーゲー |
ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
|
MX2014007725A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
CA2859862A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
AU2012355624A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CN104125954A
(zh)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
CN104136429A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
PL226174B1
(pl)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Polaczenie analogu witaminy D z imatinibem do stosowania w leczeniu skojarzonym niedrobnokomorkowego raka pluc
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
SG11201405099UA
(en)
|
2012-02-21 |
2014-10-30 |
Ranbaxy Lab Ltd |
Stable dosage forms of imatinib mesylate
|
CN102617549A
(zh)
*
|
2012-03-02 |
2012-08-01 |
瑞阳制药有限公司 |
甲磺酸伊马替尼β晶型的制备方法
|
WO2013136141A1
(en)
|
2012-03-13 |
2013-09-19 |
Fresenius Kabi Oncology Ltd. |
An improved process for the preparation of alpha form of imatinib mesylate
|
GB201204810D0
(en)
|
2012-03-20 |
2012-05-02 |
Pharos Pharmaceutical Oriented Services Ltd |
Pharmaceutical compositions
|
EP2834246B1
(en)
|
2012-04-03 |
2021-07-28 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
CN102617552A
(zh)
*
|
2012-04-06 |
2012-08-01 |
江南大学 |
一种制备α晶型甲磺酸伊马替尼的结晶方法
|
CN102633775B
(zh)
*
|
2012-04-06 |
2013-07-17 |
江南大学 |
一种甲磺酸伊马替尼α晶型的制备方法
|
JP2013216644A
(ja)
*
|
2012-04-11 |
2013-10-24 |
Takada Seiyaku Kk |
イマチニブメシル酸塩経口投与製剤
|
US20150166591A1
(en)
|
2012-05-05 |
2015-06-18 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for raf kinase mediated diseases
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
AU2013274101B2
(en)
|
2012-06-15 |
2017-09-07 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
CA2877030A1
(en)
|
2012-06-22 |
2013-12-27 |
Basf Se |
Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
|
KR101242955B1
(ko)
*
|
2012-06-25 |
2013-03-12 |
제일약품주식회사 |
이마티닙 메실레이트 결정형 α의 제조 방법
|
CN104427986A
(zh)
|
2012-07-11 |
2015-03-18 |
诺华股份有限公司 |
治疗胃肠道基质瘤的方法
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
CN104736144B
(zh)
|
2012-07-27 |
2019-02-01 |
艾祖米科技有限公司 |
外排抑制剂组合物和使用此组合物治疗的方法
|
CN103570677B
(zh)
*
|
2012-08-02 |
2017-03-01 |
广东东阳光药业有限公司 |
一种α晶型甲磺酸伊马替尼的制备方法
|
WO2014025395A1
(en)
|
2012-08-06 |
2014-02-13 |
Duke University |
Compounds and methods for targeting hsp90
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
EP2902028A1
(en)
|
2012-09-28 |
2015-08-05 |
Hangzhou Bensheng Pharmaceutical Co., Ltd. |
Drug composition for treating tumors and application thereof
|
US9439903B2
(en)
|
2012-10-25 |
2016-09-13 |
Cadila Healthcare Limited |
Process for the preparation of amorphous imatinib mesylate
|
CN105377288B
(zh)
|
2012-11-05 |
2019-11-15 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽的组合物制备药物的用途
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
EP2749269A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Process for the preparation of adsorbates of imatinib
|
EP2749271A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
EP2749557A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
GB201304699D0
(en)
|
2013-03-15 |
2013-05-01 |
Remedica Ltd |
Pharmaceutical compositions
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
ES2683361T3
(es)
|
2013-05-14 |
2018-09-26 |
Hetero Research Foundation |
Composiciones de Imatinib
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
CA3172586A1
(en)
|
2013-07-31 |
2015-02-05 |
Avalyn Pharma Inc. |
Aerosol imatininb compounds and uses thereof
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
MY184292A
(en)
|
2013-09-22 |
2021-03-30 |
Sunshine Lake Pharma Co Ltd |
Substituted aminopyrimidine compounds and methods of use
|
ES2748213T3
(es)
|
2013-10-17 |
2020-03-13 |
Sartar Therapeutics Ltd |
Composiciones que comprenden inhibidores de la fosfodiesterasa para su uso en el tratamiento de un tumor sólido en un paciente humano
|
US9636340B2
(en)
|
2013-11-12 |
2017-05-02 |
Ayyappan K. Rajasekaran |
Kinase inhibitors
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
WO2015110949A1
(en)
|
2014-01-22 |
2015-07-30 |
Novartis Ag |
Imatinib as cholesterol decreasing agent
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN103800671B
(zh)
*
|
2014-02-11 |
2016-02-10 |
王思成 |
一种治疗阿弗他溃疡的中药制剂
|
CU24481B1
(es)
|
2014-03-14 |
2020-03-04 |
Immutep Sas |
Moléculas de anticuerpo que se unen a lag-3
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
WO2015148867A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
BR112016022499A2
(pt)
|
2014-04-03 |
2017-08-15 |
Invictus Oncology Pvt Ltd |
Produtos terapêuticos combinatórios supramoleculares
|
EP2927223B1
(en)
|
2014-04-04 |
2016-06-29 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Process for preparing imatinib and salts thereof, free of genotoxic impurity f
|
CN104974133B
(zh)
*
|
2014-04-09 |
2018-04-27 |
石药集团中奇制药技术(石家庄)有限公司 |
一种甲磺酸伊马替尼晶型及其制备方法
|
CN104055745A
(zh)
*
|
2014-06-11 |
2014-09-24 |
连云港杰瑞药业有限公司 |
一种甲磺酸伊马替尼片的制备方法
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
PL3524595T3
(pl)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Management Co., Ltd. |
Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
EP3760618A1
(en)
|
2014-10-21 |
2021-01-06 |
ARIAD Pharmaceuticals, Inc. |
Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidine-2,4-diamine
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
HUE064614T2
(hu)
|
2015-02-25 |
2024-04-28 |
Eisai R&D Man Co Ltd |
Eljárás egy kinolin-származék keserû ízének elnyomására
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック,インク. |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
CN104817536A
(zh)
*
|
2015-04-14 |
2015-08-05 |
江苏豪森药业股份有限公司 |
适合药用的甲磺酸伊马替尼非针状α晶型及其制备方法
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
US10894830B2
(en)
|
2015-11-03 |
2021-01-19 |
Janssen Biotech, Inc. |
Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
|
WO2017078647A1
(en)
|
2015-11-05 |
2017-05-11 |
Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi |
Pharmaceutical compositions of imatinib
|
CN105503825B
(zh)
*
|
2015-12-16 |
2019-01-11 |
齐鲁天和惠世制药有限公司 |
一种甲磺酸伊马替尼β晶型的制备方法
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
TN2018000221A1
(en)
|
2015-12-24 |
2019-10-04 |
Takeda Pharmaceuticals Co |
Cocrystal, production method thereof, and medicament containing cocrystal
|
WO2017129624A1
(en)
|
2016-01-25 |
2017-08-03 |
Krka, D.D., Novo Mesto |
Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
|
PT3240538T
(pt)
|
2016-03-25 |
2021-12-07 |
Ab Science |
Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
|
US11261187B2
(en)
|
2016-04-22 |
2022-03-01 |
Duke University |
Compounds and methods for targeting HSP90
|
EP3257499A1
(en)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Process for preparation of imatinib methanesulfonate capsules
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
CA3034666A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
CN110036033B
(zh)
|
2016-09-27 |
2023-12-08 |
森罗治疗公司 |
嵌合吞噬受体分子
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
JP6691971B2
(ja)
|
2016-10-17 |
2020-05-13 |
Delta−Fly Pharma株式会社 |
慢性骨髄性白血病を治療又は寛解するための医薬組成物
|
US10777331B2
(en)
|
2016-11-11 |
2020-09-15 |
Curium Us Llc |
Processes for generating germanium-68 with reduced volatiles
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
KR20200100598A
(ko)
|
2017-09-26 |
2020-08-26 |
세로 테라퓨틱스, 인코포레이티드 |
키메라 포식작용 수용체 분자 및 사용 방법
|
CN111465411A
(zh)
|
2017-10-24 |
2020-07-28 |
恩科佩普股份有限公司 |
用于治疗乳腺癌的肽疫苗和派姆单抗
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
EP3740468A4
(en)
|
2018-01-20 |
2021-10-06 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
|
EP3774865A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
US20210087251A1
(en)
|
2018-03-28 |
2021-03-25 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20210024607A1
(en)
|
2018-03-28 |
2021-01-28 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
JP2024507996A
(ja)
|
2021-02-26 |
2024-02-21 |
ケロニア セラピューティクス, インコーポレイテッド |
リンパ球を標的とするレンチウイルスベクター
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
CN114957206B
(zh)
*
|
2022-04-11 |
2024-02-27 |
中国药科大学 |
伊马替尼共晶及其制备方法
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|